Τετάρτη 26 Φεβρουαρίου 2020

Evolving Treatment of Frontal Sinus Cholesteatoma: A Case Report.

Evolving Treatment of Frontal Sinus Cholesteatoma: A Case Report.:

Related Articles
Evolving Treatment of Frontal Sinus Cholesteatoma: A Case Report.

Perm J. 2020;24:

Authors: Tejani N, Kshirsagar R, Song B, Liang J

Abstract

INTRODUCTION: Cholesteatomas are lined by squamous epithelium, contain keratin debris, and can cause bony erosion. Although commonly found in the middle ear space and mastoid, cholesteatomas may develop in adjacent structures including the paranasal sinuses. Frontal sinus cholesteatoma (FSC) is a rare condition with fewer than 30 reported cases. The aims of this study are to describe the clinical presentation, diagnostic imaging, and endoscopic treatment of FSC and to review the literature focusing on the pathogenesis, diagnosis, and historical and contemporary treatments of FSC.

CASE PRESENTATION: A 45-year-old man presented with a 1-week history of right eyelid and forehead swelling. Results of computed tomography scans and magnetic resonance images revealed a right frontal sinus lesion of soft-tissue density with bony dehiscence along the superior orbit and posterior table. He underwent right-sided endoscopic sinus surgery at a tertiary care center in January 2017. Intraoperatively, the frontal sinus contained keratin debris suggestive of FSC. This suspicion was confirmed postoperatively by pathologic analysis after subtotal resection.

DISCUSSION: The pathogenesis of frontal sinus cholesteatoma varies based on its cause (congenital vs acquired). Clinical diagnosis remains challenging but is aided by nasal endoscopy, computed tomography, and magnetic resonance imaging. Historically, FSC has been managed by total extirpation through open approaches, which can entail substantial morbidity. With sophisticated endoscopic sinus instrumentation and image guidance, FSC can be successfully treated via an endoscopic approach. Serial débridements and washouts in an outpatient setting may adequately manage the residual disease in the postoperative period.

PMID: 32097113 [PubMed - as supplied by publisher]

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου